Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 8 December 1989:
Vol. 246. no. 4935, pp. 1293 - 1297
DOI: 10.1126/science.2555923
Prev | Table of Contents | Next

Articles

Science, Vol 246, Issue 4935, 1293-1297
Copyright © 1989 by American Association for the Advancement of Science

articles

A formalin-inactivated whole SIV vaccine confers protection in macaques

M Murphey-Corb, LN Martin, B Davison-Fairburn, RC Montelaro, M Miller, M West, S Ohkawa, GB Baskin, JY Zhang, SD Putney, and al. et

Delta Regional Primate Research Center, Tulane University, Covington, LA 70434.

A vaccine against human immunodeficiency virus (HIV) would be highly effective in stopping the acquired immunodeficiency syndrome (AIDS) epidemic. A comprehensive evaluation of potential vaccine methodologies can be made by means of the simian model for AIDS, which takes advantage of the similarities in viral composition and disease potential between simian immunodeficiency virus (SIV) infection of rhesus macaques and HIV infection in humans. Immunization with a formalin-inactivated whole SIV vaccine potentiated with either alum and the Syntex adjuvant threonyl muramyl dipeptide (MDP) or MDP alone resulted in the protection of eight of nine rhesus monkeys challenged with ten animal-infectious doses of pathogenic virus. These results demonstrate that a whole virus vaccine is highly effective in inducing immune responses that can protect against lentivirus infection and AIDS-like disease.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.
M. Breton, C. Zhao, M. Ouellette, M. J. Tremblay, and B. Papadopoulou (2007)
J. Gen. Virol. 88, 217-225
   Abstract »    Full Text »    PDF »
Innate and Adaptive Mucosal Immunity in Protection against HIV Infection.
L.A. Bergmeier and T. Lehner (2006)
Advances in Dental Research 19, 21-28
   Abstract »    Full Text »    PDF »
A Combination DNA and Attenuated Simian Immunodeficiency Virus Vaccine Strategy Provides Enhanced Protection from Simian/Human Immunodeficiency Virus-Induced Disease.
R. R. Amara, K. Patel, G. Niedziela, P. Nigam, S. Sharma, S. I. Staprans, D. C. Montefiori, L. Chenareddi, J. G. Herndon, H. L. Robinson, et al. (2005)
J. Virol. 79, 15356-15367
   Abstract »    Full Text »    PDF »
Inactivation of Retroviruses with Preservation of Structural Integrity by Targeting the Hydrophobic Domain of the Viral Envelope.
Y. Raviv, M. Viard, J. W Bess Jr., E. Chertova, and R. Blumenthal (2005)
J. Virol. 79, 12394-12400
   Abstract »    Full Text »    PDF »
Mucosal alloimmunization elicits T-cell proliferation, CC chemokines, CCR5 antibodies and inhibition of simian immunodeficiency virus infectivity.
L. A. Bergmeier, K. Babaahmady, Y. Wang, and T. Lehner (2005)
J. Gen. Virol. 86, 2231-2238
   Abstract »    Full Text »    PDF »
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade.
M. Giri, K. E. Ugen, and D. B. Weiner (2004)
Clin. Microbiol. Rev. 17, 370-389
   Abstract »    Full Text »    PDF »
The Trojan exosome hypothesis.
S. J. Gould, A. M. Booth, and J. E. K. Hildreth (2003)
PNAS 100, 10592-10597
   Abstract »    Full Text »    PDF »
Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection.
T. M. Allen, P. Jing, B. Calore, H. Horton, D. H. O'Connor, T. Hanke, M. Piekarczyk, R. Ruddersdorf, B. R. Mothe, C. Emerson, et al. (2002)
J. Virol. 76, 10507-10511
   Abstract »    Full Text »    PDF »
Dominance of CD8 Responses Specific for Epitopes Bound by a Single Major Histocompatibility Complex Class I Molecule during the Acute Phase of Viral Infection.
B. R. Mothe, H. Horton, D. K. Carter, T. M. Allen, M. E. Liebl, P. Skinner, T. U. Vogel, S. Fuenger, K. Vielhuber, W. Rehrauer, et al. (2002)
J. Virol. 76, 875-884
   Abstract »    Full Text »    PDF »
CD8+ Lymphocytes from Simian Immunodeficiency Virus-Infected Rhesus Macaques Recognize 14 Different Epitopes Bound by the Major Histocompatibility Complex Class I Molecule Mamu-A*01: Implications for Vaccine Design and Testing.
T. M. Allen, B. R. Mothé, J. Sidney, P. Jing, J. L. Dzuris, M. E. Liebl, T. U. Vogel, D. H. O'Connor, X. Wang, M. C. Wussow, et al. (2001)
J. Virol. 75, 738-749
   Abstract »    Full Text »
Enhanced Binding of Antibodies to Neutralization Epitopes following Thermal and Chemical Inactivation of Human Immunodeficiency Virus Type 1.
K. Grovit-Ferbas, J. F. Hsu, J. Ferbas, V. Gudeman, and I. S. Y. Chen (2000)
J. Virol. 74, 5802-5809
   Abstract »    Full Text »
Evidence for Recombination of Live, Attenuated Immunodeficiency Virus Vaccine with Challenge Virus to a More Virulent Strain.
B. R. Gundlach, M. G. Lewis, S. Sopper, T. Schnell, J. Sodroski, C. Stahl-Hennig, and K. Überla (2000)
J. Virol. 74, 3537-3542
   Abstract »    Full Text »
Env-Independent Protection Induced by Live, Attenuated Simian Immunodeficiency Virus Vaccines.
B. R. Gundlach, S. Reiprich, S. Sopper, R. E. Means, U. Dittmer, K. Matz-Rensing, C. Stahl-Hennig, and K. Uberla (1998)
J. Virol. 72, 7846-7851
   Abstract »    Full Text »    PDF »
Common Themes of Antibody Maturation to Simian Immunodeficiency Virus, Simian-Human Immunodeficiency Virus, and Human Immunodeficiency Virus Type 1 Infections.
K. S. Cole, M. Murphey-Corb, O. Narayan, S. V. Joag, G. M. Shaw, and R. C. Montelaro (1998)
J. Virol. 72, 7852-7859
   Abstract »    Full Text »    PDF »
Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins.
J. L. Rossio, M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, et al. (1998)
J. Virol. 72, 7992-8001
   Abstract »    Full Text »    PDF »
Progress in the Development of an HIV-1 Vaccine.
N. L. Letvin (1998)
Science 280, 1875-1880
   Abstract »    Full Text »
Characterization of the Peptide Binding Motif of a Rhesus MHC Class I Molecule (Mamu-A*01) That Binds an Immunodominant CTL Epitope from Simian Immunodeficiency Virus.
T. M. Allen, J. Sidney, M.-F. del Guercio, R. L. Glickman, G. L. Lensmeyer, D. A. Wiebe, R. DeMars, C. D. Pauza, R. P. Johnson, A. Sette, et al. (1998)
J. Immunol. 160, 6062-6071
   Abstract »    Full Text »    PDF »
Generation of CD8 suppressor factor and beta  chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques.
Y. Wang, L. Tao, E. Mitchell, W. M. J. M. Bogers, C. Doyle, C. A. Bravery, L. A. Bergmeier, C. G. Kelly, J. L. Heeney, and T. Lehner (1998)
PNAS 95, 5223-5228
   Abstract »    Full Text »    PDF »
Candidate AIDS Vaccines.
B. S. Graham and P. F. Wright (1995)
N. Engl. J. Med. 333, 1331-1339
   Full Text »    PDF »
Vaccines against Human Immunodeficiency Virus -- Progress and Prospects.
N. L. Letvin (1993)
N. Engl. J. Med. 329, 1400-1405
   Full Text »
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx, R. Compans, A Gettie, J. Staas, R. Gilley, M. Mulligan, G. Yamshchikov, D Chen, and J. Eldridge (1993)
Science 260, 1323-1327
   Abstract »    PDF »
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.
M. Daniel, F Kirchhoff, S. Czajak, P. Sehgal, and R. Desrosiers (1992)
Science 258, 1938-1941
   Abstract »    PDF »
Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear Cells.
P. N. Fultz, P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard (1992)
Science 256, 1687-1690
   Abstract »    PDF »
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.
S. Hu, K Abrams, G. Barber, P Moran, J. Zarling, A. Langlois, L Kuller, W. Morton, and R. Benveniste (1992)
Science 255, 456-459
   Abstract »    PDF »
The ability of certain SIV vaccines to provoke reactions against normal cells.
A. Langlois, K. Weinhold, T. Matthews, M. Greenberg, and D. Bolognesi (1992)
Science 255, 292-293
   PDF »
Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.
L Shen, Z. Chen, M. Miller, V Stallard, G. Mazzara, D. Panicali, and N. Letvin (1991)
Science 252, 440-443
   Abstract »    PDF »
The Ethical Conduct of Clinical Trials of HIV Vaccines.
W. K. Mariner (1990)
Eval Rev 14, 538-564
   Abstract »    PDF »
AIDS VACCINES: SOME PROGRESS.
(1989)
Journal Watch (General) 1989, 7
   Full Text »
Progress in vaccines against AIDS.
D. Bolognesi (1989)
Science 246, 1233-1234
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)